Moosavi F, Giovannetti E, Saso L, Firuzi O. HGF/MET pathway aberrations as diagnostic, prognostic, and predictive biomarkers in human cancers. Crit Rev Clin Lab Sci. 2019;56(8):533–66.
Article CAS PubMed Google Scholar
Fukushima T, Uchiyama S, Tanaka H, Kataoka H. Hepatocyte Growth Factor Activator: A Proteinase Linking Tissue Injury with Repair. Int J Mol Sci. 2018;19(11).
Zhang Y, Xia M, Jin K, Wang S, Wei H, Fan C, et al. Function of the c-Met receptor tyrosine kinase in carcinogenesis and associated therapeutic opportunities. Mol Cancer. 2018;17(1):45.
Article PubMed PubMed Central Google Scholar
Organ SL, Tsao MS. An overview of the c-MET signaling pathway. Ther Adv Med Oncol. 2011;3(1 Suppl):7–S19.
Naldini L, Vigna E, Bardelli A, Follenzi A, Galimi F, Comoglio PM. Biological activation of pro-HGF (hepatocyte growth factor) by urokinase is controlled by a stoichiometric reaction. J Biol Chem. 1995;270(2):603–11.
Article CAS PubMed Google Scholar
Kim HS, Chon HJ, Kim H, Shin SJ, Wacheck V, Gruver AM, et al. MET in gastric cancer with liver metastasis: the relationship between MET amplification and met overexpression in primary stomach tumors and liver metastasis. J Surg Oncol. 2018;117(8):1679–86.
Article CAS PubMed Google Scholar
Huang CY, Zhou QY, Hu Y, Wen Y, Qiu ZW, Liang MG, et al. Hepatocyte growth factor is a prognostic marker in patients with colorectal cancer: a meta-analysis. Oncotarget. 2017;8(14):23459–69.
Article PubMed PubMed Central Google Scholar
Wang M, Liang L, Lei X, Multani A, Meric-Bernstam F, Tripathy D, et al. Evaluation of cMET aberration by immunohistochemistry and fluorescence in situ hybridization (FISH) in triple negative breast cancers. Ann Diagn Pathol. 2018;35:69–76.
Article CAS PubMed Google Scholar
Rimassa L, Abbadessa G, Personeni N, Porta C, Borbath I, Daniele B, et al. Tumor and circulating biomarkers in patients with second-line hepatocellular carcinoma from the randomized phase II study with tivantinib. Oncotarget. 2016;7(45):72622–33.
Article PubMed PubMed Central Google Scholar
Neuzillet C, Couvelard A, Tijeras-Raballand A, de Mestier L, de Gramont A, Bedossa P, et al. High c-Met expression in stage I-II pancreatic adenocarcinoma: proposal for an immunostaining scoring method and correlation with poor prognosis. Histopathology. 2015;67(5):664–76.
Gao HF, Li AN, Yang JJ, Chen ZH, Xie Z, Zhang XC, et al. Soluble c-Met levels correlated with tissue c-Met protein expression in patients with Advanced Non-Small-Cell Lung Cancer. Clin Lung Cancer. 2017;18(1):85–91.
Article CAS PubMed Google Scholar
Kim JH, Kim BJ, Kim HS. Clinicopathological impacts of high c-Met expression in renal cell carcinoma: a meta-analysis and review. Oncotarget. 2017;8(43):75478–87.
Article PubMed PubMed Central Google Scholar
Choueiri TK, Vaishampayan U, Rosenberg JE, Logan TF, Harzstark AL, Bukowski RM, et al. Phase II and biomarker study of the dual MET/VEGFR2 inhibitor foretinib in patients with papillary renal cell carcinoma. J Clin Oncol. 2013;31(2):181–6.
Article CAS PubMed Google Scholar
Moch H, Amin MB, Berney DM, Compérat EM, Gill AJ, Hartmann A, et al. The 2022 World Health Organization classification of Tumours of the urinary system and male genital Organs-Part A: renal, Penile, and testicular tumours. Eur Urol. 2022;82(5):458–68.
Volpe A, Novara G, Antonelli A, Bertini R, Billia M, Carmignani G, et al. Chromophobe renal cell carcinoma (RCC): oncological outcomes and prognostic factors in a large multicentre series. BJU Int. 2012;110(1):76–83.
Erlmeier F, Feuchtinger A, Borgmann D, Rudelius M, Autenrieth M, Walch AK, et al. Supremacy of modern morphometry in typing renal oncocytoma and malignant look-alikes. Histochem Cell Biol. 2015;144(2):147–56.
Article CAS PubMed Google Scholar
Kurokawa Y, Matsuura N, Kawabata R, Nishikawa K, Ebisui C, Yokoyama Y, et al. Prognostic impact of major receptor tyrosine kinase expression in gastric cancer. Ann Surg Oncol. 2014;21(Suppl 4):584–90.
Birks DK, Kleinschmidt-DeMasters BK, Donson AM, Barton VN, McNatt SA, Foreman NK, et al. Claudin 6 is a positive marker for atypical teratoid/rhabdoid tumors. Brain Pathol. 2010;20(1):140–50.
Article CAS PubMed Google Scholar
Gao F, Li M, Xiang R, Zhou X, Zhu L, Zhai Y. Expression of CLDN6 in tissues of gastric cancer patients: Association with clinical pathology and prognosis. Oncol Lett. 2019;17(5):4621–5.
CAS PubMed PubMed Central Google Scholar
Wang Q, Zhang Y, Zhang T, Han ZG, Shan L. Low claudin-6 expression correlates with poor prognosis in patients with non-small cell lung cancer. Onco Targets Ther. 2015;8:1971–7.
CAS PubMed PubMed Central Google Scholar
Phan LM, Fuentes-Mattei E, Wu W, Velazquez-Torres G, Sircar K, Wood CG, et al. Hepatocyte growth Factor/cMET pathway activation enhances Cancer Hallmarks in Adrenocortical Carcinoma. Cancer Res. 2015;75(19):4131–42.
Article CAS PubMed PubMed Central Google Scholar
Silva Paiva R, Gomes I, Casimiro S, Fernandes I, Costa L. c-Met expression in renal cell carcinoma with bone metastases. J Bone Oncol. 2020;25:100315.
Article PubMed PubMed Central Google Scholar
Pothula SP, Xu Z, Goldstein D, Pirola RC, Wilson JS, Apte MV. Targeting HGF/c-MET Axis in Pancreatic Cancer. Int J Mol Sci. 2020;21(23).
Kim ST, Hong JY, Park SH, Park JO, Park YW, Park N, et al. First-in-human phase I trial of anti-hepatocyte growth factor antibody (YYB101) in refractory solid tumor patients. Ther Adv Med Oncol. 2020;12:1758835920926796.
Article CAS PubMed PubMed Central Google Scholar
Papaccio F, Della Corte CM, Viscardi G, Di Liello R, Esposito G, Sparano F et al. HGF/MET and the Immune System: Relevance for Cancer Immunotherapy. Int J Mol Sci. 2018;19(11).
Zambelli A, Biamonti G, Amato A. HGF/c-Met signalling in the Tumor Microenvironment. Adv Exp Med Biol. 2021;1270:31–44.
留言 (0)